KEAP1 and lung cancer: While both CDDO and its derivatives, namely CDDO‐trifluoromethyl‐amide (CDDO‐TFEA) and CDDO‐Bardoxolone‐Methyl (CDDO‐Me), activate NRF2 in a similar way, only CDDO‐Me and CDDO‐TFEA suppress BACH1 through reducing its nuclear level, making them dual KEAP1/BACH1 inhibitors impeding the invasion of lung cancer cells.[491]